Download PDF
Planta Med 2001; 67(8): 722-725
DOI: 10.1055/s-2001-18357
Original Paper
Pharmacology
© Georg Thieme Verlag Stuttgart · New York

Evaluation of In Vitro Activity of Aurones and Related Compounds against Cryptosporidium parvum

Oliver Kayser1,*, W. Ray Waters2 , Keith M. Woods3 , Steve J. Upton3 , Janet S. Keithly4 , Albrecht F. Kiderlen5
  • 1 Freie Universität Berlin, Institut für Pharmazie, Pharmazeutische Biotechnologie, Berlin, Germany
  • 2 National Animal Disease Center, Bacterial Diseases of Livestock Research Unit, Ames, Iowa, USA
  • 3 Kansas State University, Biology Department, Manhattan, Kansas, USA
  • 4 Wadsworth Center, David Axelrod Institute for Public Health, Albany, New York, USA
  • 5 Robert Koch-Institut, Berlin, Germany
Further Information

Publication History

October 27, 2000

March 6, 2001

Publication Date:
09 November 2001 (online)

    Permissions and Reprints

Abstract

The efficacy of a series of aurones, auronols and 4-methoxy-α-pyrones has been screened for the ability to inhibit the intracellular growth of the parasitic protist Cryptosporidium parvum using an in vitro enzyme linked immunosorbent assay (ELISA). All aurones of this series were active at 25 to 100 μM. 10 of 19 aurones inhibited the intracellular growth of C. parvum by > 90 % with moderate to no toxicity. The most active of these was 3′,4′,6-trihydroxy-2-[phenylmethylene]-3(2H)-benzofuranone.

Key words

Aurones - Cryptosporidium - ELISA assay - protist chemotherapy - drug testing

References

  • 1 Laing R B. Nosocomial infections in patients with HIV disease.  Journal of Hospital Infection. 1999;  43 179-85
    CrossrefPubMedGoogle Scholar
  • 2 Ramratnam B, Flanigan T P. Cryptosporidiosis in persons with HIV infection.  Postgraduate Medicine. 1997;  73 713-6
    PubMedGoogle Scholar
  • 3 Das P. Cryptosporidium related diarrhoea.  Indian Journal of Medicinal Research. 1996;  104 86-95
    PubMedGoogle Scholar
  • 4 Woods K M, Nesterenko M V, Upton S J. Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro .  Annals of Tropical Medicine and Parasitology. 1996;  90 603-15
    PubMedGoogle Scholar
  • 5 Sharma P, Sharma J D. Plants showing antiplasmodial activity - from crude extracts to isolated compounds.  Indian Journal of Malariology. 1998;  35 57-110
    PubMedGoogle Scholar
  • 6 van Agtmael M A, Eggelte T a, van Boxtel C J. Artemisinin drugs in the treatment of Malaria: From medicinal herb to registered medication.  Trends in Pharmacological Sciences. 1999;  20 199-205
    CrossrefPubMedGoogle Scholar
  • 7 Sepúvelda-Boza S, Cassels B K. Plant metabolites active against Trypanosoma cruzi .  Planta Medica. 1996;  62 98-105
    PubMedGoogle Scholar
  • 8 Bley K. Darstellung einiger Auronole (= 2-Benzoylcumaranone-(3)) und analytischer Vergleich mit entsprechend substituierten Flavonolen. PhD Dissertation 1970 Freie Universität Berlin;
    Google Scholar
  • 9 Woods K M, Nesterenko M V, Upton S J. Development of a microtiter ELISA to quantify development of Cryptosporidium parvum in vitro .  FEMS Microbiology Letters. 1995;  128 89-93
    CrossrefPubMedGoogle Scholar
  • 10 Upton S J. In vitro cultivation. In R. Fayer, (ed.) Cryptosporidium and Cryptosporidiosis, 1st ed. CRC Press Boca Raton, Fl.; 1997: p. 181-207
    Google Scholar
  • 11 Upton S J, Tilley M, Brillhart D B. Effects of select medium supplements on in vitro development of Cryptosporidium parvum in HCT-8 cells.  Journal of Clinical Microbiology. 1995;  33 371-5
    PubMedGoogle Scholar

Dr. Oliver Kayser

Freie Universität Berlin

Institut für Pharmazie

Pharmazeutische Biotechnologie

Kelchstraße 31

12169 Berlin

Germany

Email: kayser@zedat.fu-berlin.de

Fax: +49-30-838 50605

Phone: Tel.: +49-30-838 50689

      >